Table 4.
Relation between GSK3β Levels and clinic outcome
| Dialysis-free survivala | Renal event-free survivala | Slope of eGFR declineb | |
|---|---|---|---|
| (A) Urinary levels | |||
| Urinary level by ELISA | |||
| Entire cohort | 1.00 (0.99–1.02), p = 0.693 | 1.00 (0.98–1.02), p = 0.849 | r = −0.029, p = 0.698 |
| DKD group | 0.99 (0.98–1.02), p = 0.858 | 1.00 (0.98–1.02), p = 0.957 | r = −0.004, p = 0.970 |
| Nondiabetic CKD group | 0.94 (0.87–1.01), p = 0.102 | 0.89 (0.81–0.99), p = 0.031 | r = 0.081, p = 0.474 |
| Urinary mRNA level | |||
| Entire cohort | 1.02 (0.86–1.22), p = 0.808 | 0.96 (0.80–1.14), p = 0.623 | r = −0.011, p = 0.876 |
| DKD group | 1.06 (0.84–1.33), p = 0.645 | 0.95 (0.76–1.18), p = 0.625 | r = 0.020, p = 0.851 |
| Nondiabetic CKD group | 0.96 (0.74–1.24), p = 0.754 | 0.97 (0.73–1.30), p = 0.849 | r = −0.074, p = 0.507 |
| Urinary p-GSK3β level | |||
| Entire cohort | 0.80 (0.52–1.23), p = 0.307 | 0.92 (0.65–1.32), p = 0.655 | r = 0.018, p = 0.816 |
| DKD group | 0.72 (0.42–1.21), p = 0.212 | 0.83 (0.53–1.30), p = 0.412 | r = 0.020, p = 0.856 |
| Nondiabetic CKD group | 1.07 (0.58–1.99), p = 0.829 | 1.02 (0.60–1.73), p = 0.941 | r = −0.096, p = 0.372 |
| p-GSK3β/total GSK3β ratio | |||
| Entire cohort | 0.00 (0.00–33.92), p = 0.278 | 0.00 (0.00–30.51), p = 0.553 | r = 0.062, p = 0.382 |
| DKD group | 0.00 (0.00–24.18), p = 0.242 | 0.00 (0.00–26.23), p = 0.399 | r = 0.041, p = 0.712 |
| Nondiabetic CKD group | 369.50 (0.00–62.00), p = 0.735 | 1,058.93 (0.00–57.61), p = 0.829 | r = −0.093, p = 0.401 |
| (B) Intrarenal levels | |||
| Total GSK3β | |||
| Entire cohort | 1.14 (0.76–1.70), p = 0.534 | 1.02 (0.695–1.51), p = 0.905 | r = −0.220, p = 0.054 |
| DKD group | 0.86 (0.48–1.54), p = 0.619 | 0.94 (0.51–1.72), p = 0.850 | r = −0.122, p = 0.328 |
| Nondiabetic CKD group | 0.14 (0.00–6.83), p = 0.139 | 1.59 (0.21–12.10), p = 0.655 | r = 0.135, p = 0.730 |
| pY216-GSK3β | |||
| Entire cohort | 0.93 (0.67–1.29), p = 0.652 | 1.24 (0.91–1.68), p = 0.168 | r = −0.228, p = 0.058 |
| DKD group | 0.93 (0.67–1.30), p = 0.670 | 1.26 (0.92–1.72), p = 0.152 | r = −0.221, p = 0.075 |
| Nondiabetic CKD group | 0.62 (0.04–9.73), p = 0.731 | 1.14 (0.11–11.70), p = 0.915 | r = −0.632, p = 0.368 |
| pY216-GSK3β/total GSK3β ratio | |||
| Entire cohort | 0.95 (0.51–1.76), p = 0.870 | 1.21 (0.72–2.02), p = 0.477 | r = 0.069, p = 0.568 |
| DKD group | 0.82 (0.26–1.2.53), p = 0.724 | 2.47 (0.89–6.82), p = 0.081 | r = −0.335, p = 0.006 |
| Nondiabetic CKD group | 0.64 (0.01–24.17), p = 0.811 | 1.61 (0.08–33.8), p = 0.759 | r = −0.600, p = 0.400 |
DKD, diabetic kidney disease; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
Results are depicted as aunadjusted hazard ratio (95% confidence interval) and bPearson’s correlation coefficient.